Daniel L. Maxwell, D.O., FACOI Assistant Professor of Medicine Michigan State University College of Osteopathic Medicine College of Human Medicine
|
|
|
- Carol Ferguson
- 7 years ago
- Views:
Transcription
1 New Medications in the Treatment of COPD Daniel L. Maxwell, D.O., FACOI Assistant Professor of Medicine Michigan State University College of Osteopathic Medicine College of Human Medicine Alpena Regional Medical Center Alpena, MI
2 Alpena
3 Objectives Review pathophysiology of COPD Review new methods of inhaled medication delivery Identify newly (or soon to be) available therapeutic agents for the treatment of COPD and their place in the therapeutic armamentarium
4 COPD Chronic Obstructive Pulmonary Disease (COPD) is a common preventable and treatable disease Characterized by persistent airflow limitation that is usually progressive and associated with an enhanced chronic inflammatory response in the airways and the lung to noxious particles or gases. Exacerbations and comorbidities contribute to the overall severity in individual patients.
5 Healthcare Costs $ 49.9 Billion Total Annual Costs $ 29.5 Billion Direct Costs ~ 16.3 Million Office Visits ~ 1.5 Million ED Visits $ 20.4 Billion Indirect Costs Lost work time Patient and Family Members
6 Healthcare Costs Direct Costs Between 50 and 75% Due to Exacerbations ~ $ 7,200 / routine admission ~ $ 21,000 / severe admission ~ $ 45,000 / ICU admission mechanical ventilation
7 COPD 3 rd Heart diseases Cancers COPD Strokes Accidents 8.5% leading cause of death in the US 1-6.3% -1.1% -8.2% -3.9% Only leading cause of death which increased from
8 COPD Risk Factors Complex Gene / Environment Interaction Familial Risk of airflow obstruction in NonSmoking Siblings of Patients with COPD Alpha-1-antiprotease deficiency Other (genome-wide association studies) Less Clear Association Matrix Metalloproteinase 12 Hedge-hog interacting protein Alpha-nicotinic acetylcholine receptor
9 COPD Risk Factors Tobacco Smoking Cigarettes Cigar / Pipe Environmental Smoke ( second hand ) Home / Workplace Other Leafy Substances
10 COPD Risk Factors Air Pollution Urban Environment Socioeconomic Status Smoking Prevalence Other Factors Not well defined Environmental air Poor nutrition Crowding Recurrent Infections
11 COPD Pathophysiology Chronic Airflow Obstruction Obstructive Bronchiolitis (Small airways disease) Parenchymal Destruction Loss of alveolar tethering Bronchomotor Tone Chronic Airway Inflammation Structural Changes Small Airway Narrowing
12 Treatment Goals Reduce COPD symptoms Decrease frequency and severity of exacerbations Improve health status and exercise tolerance Reduce Mortality Oxygen
13 Treatment Goals Reduce Disease Progression No treatment shown to decrease the inexorable decline in pulmonary function Reduction in exacerbations may reduce progression by decreasing lung injury
14 Treatment Nonpharmacologic Smoking Cessation Nutritional Support Patient Education Mechanical Devices Improve secretion clearance Acapella Flutter
15 Treatment Nonpharmacologic Pulmonary Rehabilitation No improvement in lung function Improvement in exercise tolerance / VO2 max Improved Quality of Life Decreased Hospitalization Vaccination
16 Vaccination Influenza (AIV) Annual trivalent / tetravalent Pneumococcal polysaccharide (PPSV23) 6 10 years Pneumococcal conjugate (PCV13) New recommendations CDC (Sept 2014) > 65 y/o 1 dose Separated from AIV and PPSV23
17 Pharmacologic Options Inhaled Beta 2 Agonists Short Acting Long Acting Anticholinergics (AntiMuscarinics) Short Acting Corticosteroids Combination Products Long Acting
18 Pharmacologic Options Systemic Methylxanthenes Theophylline Caffeine Oxygen Phosphodiesterase 4 Inhibitors
19 3,5 camp Secondary intracellular messenger Regulates post-translational modification (phosphorylation)of multiple intracellular enzymes Adenylyl cyclase Cyclic Nucleotide Phosphodiesterases (1 11) cgmp selective (5, 6, 9) camp selective (4, 7, 8) Nonselective (1, 2, 3, 10, 11)
20 3,5 camp Hydrolyzes 3,5 camp to 5 AMP Increased intracellular camp levels Goblet cell hyperplasia Increased eosinophil (neutrophil) infiltration/activation Lung Inflammation / Injury Airway Remodeling
21 Phosphodiesterase 4 (PDE 4) Inhibition Decreased eosinophil infiltration, lung injury, airway wall thickness, goblet cell hyperplasia Decreased secretions
22 PDE 4 Inhibitors Rofumilast Reduced PMNs (31%) Eosinophils (42%) 17% reduction in moderate to severe exacerbations Number Needed to Treat: 4.35
23 Delivery Devices Metered Dose Inhalers Dry Powder Inhalers Soft Mist Inhalers Aerosol Nebulizers
24 Metered Dose Inhalers CFC (Freon 12) Discontinued Beginning 2008 Albuterol Last 31 Dec 2013 Combivent (albuterol/ipratropium) Maxair (pirbuterol)
25 Metered Dose Inhalers HFA (HydroFlouroAlkane) r134a Qualitatively different from CFC inhalers Warmer More viscous Less forceful Cannot use float technique
26 Dry Powder Inhalers Manufacturer Specific Capsule Self-Contained
27 Capsule Inhalers Neohaler Arcapta (indacaterol) Seebri (glycopyrronium) Aerolizer Foradil (formoterol)
28 Capsule Inhalers HandiHaler Spiriva (tiotropium)
29 Self Contained Inhalers Twisthaler Asmanex (mometasone) Flexhaler Pulmicort (budesonide)
30 Self Contained Inhalers Preshaler Tudorza (aclidinium) Discus Advair (fluticasone/salmeterol) Serevent (salmeterol) Flovent (fluticasone)
31 Self Contained Inhalers Ellipta Breo (fluticasone/vilanterol) Anoro (vilanterol/umeclodinium) Incruse (umeclodinium) Arnuity (fluticasone furoate)
32 Soft Mist Inhalers Respimat CombiVent (albuterol/ ipratropium) Spiriva (tiotropium) Striverdi (olodaterol) olodaterol/tiotropium
33 Pharmacologic Options Inhaled Beta 2 Agonists Short Acting Long Acting Anticholinergics (AntiMuscarinics) Short Acting Corticosteroids Combination Products Long Acting
34 Short Acting Beta Agonists (SABA) Historical Epinephrine (Primatene Mist) Isoproterenol (Isuprel) Isoetharene (Bronkometer) Metaproterenol (Alupent) Current Albuterol (Ventolin, Proventil, ProAir) Levalbuterol (Xopenex)
35 Short Acting Anticholinergics (SAMA) Ipratropium Atrovent HFA (2004)
36 Long Acting Beta Agonists (LABA) Black Box Warning (Asthma) No similar warning for COPD
37 Long Acting Beta Agonists (LABA) Salmeterol (1994) (Serevent) Formoterol (2001) (Foradil)
38 Long Acting Beta Agonists (LABA) Indacaterol (2011) (Arcapta) 75 mcg dosage European approval 150 and 300 mcg Vilanterol (2013 as combination therapy) (not marketed independently) Olodaterol (2014) (Striverdi)
39 Long Acting Anticholinergics (LAMA) Aclidinium (2012) (Tudorza)
40 Long Acting Anticholinergics (LAMA) Tiotropium (2004) (Spiriva) Umeclodinium (2014) (Incruse) Glycopyrronium/NVA237 (pending) (Seebri)
41 Inhaled Corticosteroids (ICS) Fluticasone Propionate (Flovent) Furoate (Arnuity) Mometasone (Asmanex) Budesonide (Pulmicort)
42 Combinations LABA / ICS Advair (2000/2003) (Fluticasone Proprionate / Salmeterol) Symbicort (2006/2009) (Budesonide / Formoterol) Dulera (2010) (Mometasone / Formoterol)
43 Combinations LABA/ICS Breo (Fluticasone furoate / Vilanterol) Boehringer Ingelheim (unknown / Olodaterol)
44 Combinations LABA/LAMA Anoro (Vilanterol/Umeclodinium)
45 Combinations LABA/LAMA Actavis (Formoterol/Aclidinium) FDA submission pending Boehringer Ingelheim (Tiotropium/Olodaterol) Phase 3 trials Ultibro/Xoterna/QVA149 (Indacaterol/Glycopyrronium) European approval US Phase 3 trials
46 Combinations LABA / LAMA / ICS GlaxoSmithKline Vilanterol / Umeclodinium / Fluticasone Furoate Phase 3 Trials
47 GOLD Guidelines Originally 2001 Updates 2003, 2004, 2006, 2007, 2010 Treatment recommendations based on severity of airflow obstruction
48 GOLD Guidelines Major Revision 2011 Updated 2013, 2014 Treatment based on a combined assessment of symptoms/risk of exacerbations and airflow obstruction
49 Combined Assessment Assess symptoms Assess risk of exacerbations Assess degree of airflow limitation using spirometry Combine these assessments for the purpose of improving management of COPD 2014 Global Initiative for Chronic Obstructive Lung Disease
50 Symptoms COPD Assessment Test (CAT) Clinical COPD Questionnaire (CCQ) Modified British Medical Research Council Questionnaire (mmrc) 2014 Global Initiative for Chronic Obstructive Lung Disease
51 Risk of Exacerbation High Risk > 2 exacerbations / year or > 1 hospitalization / year or FEV1< 50% predicted
52 Airflow Obstruction FEV1/FVC ratio < 0.70 Mild (GOLD 1) FEV1 > 80% predicted Moderate (GOLD 2) 50% < FEV1 < 80% Severe (GOLD 3) 30% < FEV1 < 50% Very Severe (GOLD 4) FEV1 < 30%
53 Risk (GOLD Classification of Airflow Limitation)) Risk (Exacerbation history) Combined Assessment (C) (D) or > 1 (leading to hospital admission) 2 (A) (B) 1 (not leading to hospital admission) 1 0 CAT < 10 CAT > 10 mmrc 0 1 mmrc > 2 Symptoms 2014 Global Initiative for Chronic Obstructive Lung Disease
54 Treatment Recommendations Goals Decrease symptoms Decrease exacerbations Improve exercise tolerance Improve health status
55 Treatment Recommendations Risk Based Severity of Disease GOLD Grouping Combined Assessment
56 All Patients (GOLD A D) Smoking Cessation Patient Education Nutritional Support Vaccination Pulmonary Rehabilitation Symptomatic / Increased risk (GOLD B D)
57 Pharmacologic All Patients Short Acting Bronchodilators prn use SABA (albuterol or levalbuterol) SAMA (ipratropium) SABA+SAMA (Combivent)
58 GOLD A Less Symptomatic / Minimal Airflow Obstruction / Low Risk of Exacerbations prn bronchodilators SABA or SAMA SABA+SAMA
59 GOLD B More Symptomatic / Limited Airflow Obstruction / Low Risk of Exacerbations Nature of Symptoms Dyspnea / Exertional Dyspnea Sputum Production
60 GOLD B More Symptomatic / Limited Airflow Obstruction / Low Risk of Exacerbations Dyspnea LABA LAMA Persistent Symptoms LABA+LAMA
61 GOLD B More Symptomatic / Limited Airflow Obstruction / Low Risk of Exacerbations Sputum Production LABA / ICS LAMA / ICS Exacerbations GOLD C
62 GOLD C Less Symptomatic / Severe Airflow Obstruction / Higher Risk of Exacerbation LABA / ICS LAMA Exacerbations Add PDE4 Inhibitor
63 GOLD D More Symptomatic / Severe Airflow Obstruction / High Risk of Exacerbation LABA / ICS LAMA LABA / LAMA / ICS LAMA / ICS Exacerbations Add PDE4 Inhibitor
64 Not Recommended Antioxidants Oral Mucolytics guiafenesin, iodinated glycerol, etc. N-acetylcysteine Inhaled corticosteroids (monotherapy) Systemic corticosteroids (chronic) Theophylline
65 Summary Multiple new therapeutic options for the treatment of COPD 1 new class of agents: PDE4-Inhibitors New variations on a theme
66 Summary Long acting bronchodilators More convenient and effective for symptom relief Daily dosing: improved compliance
67 Summary Combination Therapy Improved compliance Reduced cost Improved efficacy Reduced side effects Compared to increased dose of single agent
68 Summary Single Daily Dosing LABA Indacaterol Vilanterol Olodaterol LAMA Aclidinium (BID) Umeclodinium Glycopyrronium
69 Summary Single Daily Dosing LABA/LAMA Vilanterol/Umeclodinium (Anoro) Olodaterol/Tiotropium Indacaterol/Glycopyrronium LABA/ICS Vilanterol/Fluticasone furoate (Breo) unknown/olodaterol
70 Summary Phosophodiesterase 4 Inhibitors Rofumilast (Daliresp)
71 Summary Exciting time in Pulmonary Medicine Many new and upcoming agents Improve compliance Improve symptoms Reduce costs Patients and Insurance co.
72 Questions?
GEORGIA MEDICAID FEE-FOR-SERVICE ASTHMA and COPD AGENTS PA SUMMARY
GEORGIA MEDICAID FEE-FOR-SERVICE ASTHMA and COPD AGENTS PA SUMMARY Preferred Anticholinergics and Combinations Atrovent HFA (ipratropium) Combivent Respimat (ipratropium/albuterol) Ipratropium neb inhalation
Medications for Managing COPD in Hospice Patients. Jim Joyner, PharmD, CGP Director of Clinical Operations Outcome Resources
Medications for Managing COPD in Hospice Patients Jim Joyner, PharmD, CGP Director of Clinical Operations Outcome Resources Goal of medications in COPD Decrease symptoms and/or complications Reduce frequency
Prevention of Acute COPD exacerbations
December 3, 2015 Prevention of Acute COPD exacerbations George Pyrgos MD 1 Disclosures No funding received for this presentation I have previously conducted clinical trials with Boehringer Ingelheim. Principal
AECOPD: Management and Prevention
AECOPD: Management and Prevention Neil MacIntyre MD Duke University Medical Center Durham NC AECOPD: Management and Prevention AECOPD: Definitions and impact Acute management of AECOPD Preventing AECOPD.
Before prescribing for COPD management, the patient should have had appropriate assessment, including spirometry, as per NICE guidelines.
Formulary Guidance for Management of COPD patients Before prescribing for COPD management, the patient should have had appropriate assessment, including spirometry, as per NICE guidelines. For inhaler
COPD and Asthma Differential Diagnosis
COPD and Asthma Differential Diagnosis Chronic Obstructive Pulmonary Disease (COPD) is the third leading cause of death in America. Learning Objectives Use tools to effectively diagnose chronic obstructive
Understanding COPD. Carolinas Healthcare System
Understanding COPD Carolinas Healthcare System 2013 This self-directed learning module contains information about the pathophysiology, diagnosis, and treatment of COPD. Target Audience: All RNs and LPNs
Pharmacology of the Respiratory Tract: COPD and Steroids
Pharmacology of the Respiratory Tract: COPD and Steroids Dr. Tillie-Louise Hackett Department of Anesthesiology, Pharmacology and Therapeutics University of British Columbia Associate Head, Centre of Heart
Stacie L. Penkova, PharmD, MHSA, BCPS Clinical Pharmacy Manager Critical Care Pharmacy Specialist Drug Information Coordinator Pharmacology Summit
Stacie L. Penkova, PharmD, MHSA, BCPS Clinical Pharmacy Manager Critical Care Pharmacy Specialist Drug Information Coordinator Pharmacology Summit July 26, 2014 Objectives Classify asthma by severity Prescribe
COPD Prescribing Guidelines
South Staffordshire Area Prescribing Group COPD Prescribing Guidelines Inhaler choices in this guideline are different from previous versions produced by the APG. It is not expected patients controlled
COPD PROTOCOL CELLO. Leiden
COPD PROTOCOL CELLO Leiden May 2011 1 Introduction This protocol includes an explanation of the clinical picture, diagnosis, objectives and medication of COPD. The Cello way of working can be viewed on
RES/006/APR16/AR. Speaker : Dr. Pither Sandy Tulak SpP
RES/006/APR16/AR Speaker : Dr. Pither Sandy Tulak SpP Definition of Asthma (GINA 2015) Asthma is a common and potentially serious chronic disease that imposes a substantial burden on patients, their families
Chronic obstructive pulmonary disease (COPD)
Chronic obstructive pulmonary disease (COPD) Chronic obstructive pulmonary disease (COPD) is the name for a group of lung diseases including chronic bronchitis, emphysema and chronic obstructive airways
YOU VE BEEN REFERRED TO AN ASTHMA SPECIALIST...
YOU VE BEEN REFERRED TO AN ASTHMA SPECIALIST... ...HERE S WHAT TO EXPECT You have been referred to an allergist because you have or may have asthma. The health professional who referred you wants you to
Glucocorticoids, Inhaled Therapeutic Class Review (TCR)
Glucocorticoids, Inhaled Therapeutic Class Review (TCR) July 31, 2015 No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying,
Pathway for Diagnosing COPD
Pathway for Diagnosing Visit 1 Registry Clients at Risk Patient presents with symptoms suggestive of Exertional breathlessness Chronic cough Regular sputum production Frequent bronchitis ; wheeze Occupational
Prof. Florian Gantner. Vice President Respiratory Diseases Research Boehringer Ingelheim
Prof. Florian Gantner Vice President Respiratory Diseases Research Boehringer Ingelheim Research and Development in Practice: COPD Chronic Obstructive Pulmonary Disease (COPD) Facts Main cause of COPD
Topic: New Treatment = Better Outcome?
Session on COPD: Novel Concepts and Promising New Drugs Topic: New Treatment = Better Outcome? Through a CME Grant sponsored by New Treatment = Better Outcome? Tim S. Trinidad, MD Disclosure Present: COPD
Understanding COPD. An educational health series from
Understanding COPD An educational health series from Our Mission since 1899 is to heal, to discover, and to educate as a preeminent healthcare institution. We serve by providing the best integrated and
COPD. (Chronic Obstructive Pulmonary Disease) (Emphysema) (Chronic Bronchitis) Education For Our Community
COPD (Chronic Obstructive Pulmonary Disease) (Emphysema) (Chronic Bronchitis) Education For Our Community Chronic Obstructive Pulmonary Disease (COPD) Definition Chronic obstructive pulmonary disease (COPD)
Bronchodilators in COPD
TSANZSRS Gold Coast 2015 Can average outcomes in COPD clinical trials guide treatment strategies? Long live the FEV1? Christine McDonald Dept of Respiratory and Sleep Medicine Austin Health Institute for
David J. Lederer, MD, MS
COPD: Definition Chronic Obstructive Pulmonary Disease Chronic airflow obstruction due to chronic bronchitis and/or pulmonary emphysema David J. Lederer, MD, MS Associate Medical Director, Lung Transplant
medicineupdate to find out more about this medicine
medicineupdate Asking the right questions about new medicines Seretide for chronic obstructive pulmonary disease What this medicine is 1 What this medicine treats 2 Other medicines available for this condition
Sponsor Novartis Pharmaceuticals
Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Generic Drug Name Indacaterol Therapeutic Area of Trial Chronic Obstructive Pulmonary Disease (COPD) Indication studied: COPD Study
COPD MANAGEMENT PROTOCOL STANFORD COORDINATED CARE
I. PURPOSE To establish guidelines f the collabative management of patients with a diagnosis of chronic obstructive pulmonary disease (COPD) who are not adequately controlled and to define the roles and
Living Well With COPD Chronic Bronchitis and Emphysema
Living Well With COPD Chronic Bronchitis and Emphysema YOUR PATIENT GUIDE AMERICAN COLLEGE OF CHEST PHYSICIANS AND THE CHEST FOUNDATION Living Well With COPD Chronic Bronchitis and Emphysema YOUR PATIENT
COPD RESOURCE PACK SECTION 11. Fife Integrated COPD Care Pathways
COPD RESOURCE PCK SECTION 11 Fife Integrated COPD Care Pathways In this section: 1. COPD Guidance treatment at each stage of the disease 2. Overview of Respiratory (COPD) Integrated Pathway 3. Chronic
Chronic Obstructive Pulmonary Disease
COPD Guideline Team Team Leader Davoren A Chick, MD General Medicine Team Members Paul J Grant, MD General Medicine Meilan K Han, MD, MS Pulmonary Medicine R Van Harrison, PhD Medical Education Elisa B
Highlights for COPD Management
COPD NEW DRUGS, NEW DEVICES AND CONSIDERATIONS FOR BEST PRACTICE September 2015 INSIDE Pg 2: COPD Overview - a birds eye view Pg 3: COPD Pharmacotherapy Comparison Chart - sorting out all the medication
Glucocorticoids, Inhaled Therapeutic Class Review (TCR) February 7, 2012
Glucocorticoids, Inhaled Therapeutic Class Review (TCR) February 7, 2012 No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying,
Asthma & COPD Medication List
Asthma & COPD Medication List LONG-TERM CONTROL MEDICATIONS (used for prevention / control of asthma, NOT treatment of acute exacerbations) a. INHALED CORTICOSTEROIDS (ICS) Drug of choice for all levels
Drug therapy SHORT-ACTING BETA AGONISTS SHORT-ACTING ANTICHOLINERGICS LONG-ACTING BETA AGONISTS LONG-ACTING ANTICHOLINERGICS
Drug therapy 6 6.1 What is the role of bronchodilators in COPD? 52 SHORT-ACTING BETA AGONISTS 6.2 How do short-acting beta agonists work? 52 6.3 What are the indications for their use? 52 6.4 What is the
RSPT 1410 Common Respiratory Drugs
1 RSPT 1410 Wilkins: Chapter 32 2 Classifications Respiratory therapists administer several different class of drugs: (adrenergic) Parasympatholytics (anticholinergic) Mucoactives (mucolytic) Antiasthmatics
Living Well With COPD Chronic Bronchitis and Emphysema
Living Well With COPD Chronic Bronchitis and Emphysema Your Patient workbook AMERICAN COLLEGE OF CHEST PHYSICIANS AND THE CHEST FOUNDATION Living Well With COPD Chronic Bronchitis and Emphysema your patient
Global Initiative for Chronic Obstructive Lung Disease
Global Initiative for Chronic Obstructive Lung Disease POCKET GUIDE TO COPD DIAGNOSIS, MANAGEMENT, AND PREVENTION A Guide for Health Care Professionals REVISED 2011 Global Initiative for Chronic Obstructive
Financial Disclosure. Pharmacy Technician Objectives: Definition: Pediatric Asthma Incidence, Pathogenesis, Severity and Treatment
Pediatric Asthma Incidence, Pathogenesis, Severity and Treatment Roger Hefflinger, Pharm.D. Clinical Associate Professor Family Medicine Residency of Idaho Idaho State University College of Pharmacy Financial
5. Aerosol Drug Delivery Devices: Pressurized Metered-Dose Inhalers
Table of Contents Introduction 1. Aerosol Drug Delivery: the Basics 2. Aerosol Drugs: the Major Categories 3. Aerosol Drug Delivery Devices: Small-Volume Nebulizers 4. Aerosol Drug Delivery Devices: Inhalers
Pre-Operative Services Teaching Rounds 2 Jan 2011
Pre-Operative Services Teaching Rounds 2 Jan 2011 Deborah Richman MBChB FFA(SA) Director Pre-Operative Services Department of Anesthesia Stony Brook University Medical Center, NY drichman@notes.cc.sunysb.edu
EMS Information Bulletin- #060
BUREAU OF EMERGENCY MEDICAL SERVICES EMS Information Bulletin- #060 DATE: October 27, 2008 SUBJECT: TO: FROM: Continuous Positive Airway Pressure for Basic Life Support Pennsylvania EMS Organizations &
Classifying Asthma Severity and Initiating Treatment in Children 0 4 Years of Age
Classifying Asthma Severity and Initiating Treatment in Children 0 4 Years of Age Components of Severity Symptoms Intermittent 2 days/week Classification of Asthma Severity (0 4 years of age) Persistent
Breath of Fresh Air. In Case of Emergency. Information, news and advice for improving asthma well-being
Information, news and advice for improving asthma well-being Volume 11, No. 2 Winter 2009 In Case of Emergency Have a plan. A plan to deal with an asthma attack is the best defense against the severe,
CCHCS Care Guide: Asthma
GOALS SHORTNESS OF BREATH, WHEEZE, COUGH NIGHT TIME AWAKENINGS ACTIVITY INTERFERENCE SABA* USE FOR SYMPTOM CONTROL FEV1* OR PEAK FLOW EXACERBATIONS REQUIRING ORAL STEROIDS < 2 DAYS / WEEK 2 TIMES / MONTH
Compare the physiologic responses of the respiratory system to emphysema, chronic bronchitis, and asthma
Chapter 31 Drugs Used to Treat Lower Respiratory Disease Learning Objectives Describe the physiology of respirations Compare the physiologic responses of the respiratory system to emphysema, chronic bronchitis,
Respiratory Therapy Self Assessment
Respiratory Therapy Self Assessment Directions Please circle a value for each question to provide us and the interested facilities with an assessment of your clinical experience. These values confirm your
Kortverk. betaagonist. Grönmarkerat är rekommenderat i första hand vid KOL resp astma för vuxna och barn >7år. Antikolinergika.
Aerobec och Autohaler spray 50 och 100 µg/dos Anoro Ellipta 55/22 µg/dos Airflusal Forspiro 50/250 och 50/500 µg/dos Vilanterol Umeklidinium Airomir 0,1mg/dos Autohaler spray 0,1mg/dos Airsalb 0,1mg/ dos
COPD. What is COPD? How many people have COPD in Canada? Who gets COPD?
What is COPD? COPD stands for Chronic Obstructive Pulmonary Disease. It is a long-term lung disease that makes it difficult for air to move into and out of the lungs. COPD is used to describe a few lung
Post-market review of COPD medicines. Joint submission from Lung Foundation Australia (LFA) and Thoracic Society of Australia and New Zealand (TSANZ)
Post-market review of COPD medicines Joint submission from Lung Foundation Australia (LFA) and Thoracic Society of Australia and New Zealand (TSANZ) EXECUTIVE SUMMARY With the addition of new medicines
Guidance to support the stepwise review of combination inhaled corticosteroid therapy for adults ( 18yrs) in asthma
Guidance to support the stepwise review of combination inhaled corticosteroid therapy for adults ( 18yrs) in asthma Important Complete asthma control needs to be achieved for at least 12 weeks before attempting
Produced by the American Association for Respiratory Care Copyright 2013 by the American Association for Respiratory Care
Produced by the American Association for Respiratory Care Copyright 2013 by the American Association for Respiratory Care Supported by an educational grant from Philips Respironics Foreword (Second Edition)
On completion of this chapter you should be able to: discuss the stepwise approach to the pharmacological management of asthma in children
7 Asthma Asthma is a common disease in children and its incidence has been increasing in recent years. Between 10-15% of children have been diagnosed with asthma. It is therefore a condition that pharmacists
Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease
Page 1 of 67 AJRCCM Articles in Press. Published on August 9, 2012 as doi:10.1164/rccm.201204-0596pp GOLD Executive Summary Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive
Medications. Patient Education Pulmonary Rehabilitation. A guide to medications for Chronic Obstructive Pulmonary Disease (COPD) Introduction
Patient Education A guide to medications for Chronic Obstructive Pulmonary Disease (COPD) Do you know how each of your inhalers works to help your breathing? Do you know the correct order in which to use
Corticosteroids for COPD Exacerbation
PL Detail-Document #290801 This PL Detail-Document gives subscribers additional insight related to the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER August 2013 Corticosteroids
Pulmonary Rehabilitation in Newark and Sherwood
Pulmonary Rehabilitation in Newark and Sherwood With exception of smoking cessation pulmonary rehabilitation is the single most effective intervention for any patient with COPD. A Cochrane review published
From the Text. History & Development. History & Development. Clinical Indications. Clinical Indications. RSPT 2317 Sympathomimetics - Part 1
RSPT 2217 Adrenergic Bronchodilators (Sympathomimetics) Gardenhire Chapter 6 From the Text Key Terms and Definitions Page 104 Current Adrenergic Bronchodilators Table 6-1; page 106 Effects & Characteristics
COPD Intervention. Components:
COPD Intervention 1. Primary disease education Member will have an increased understanding of chronic obstructive pulmonary disease, the causes, risks and complications. Explain COPD Explain how COPD is
RESPIRATORY MEDICATIONS
RESPIRATORY MEDICATIONS Purpose: To define and describe medications administered by Respiratory Therapy to patients. Sympathetic receptors: 1. Alpha receptors: - found primarily in blood vessels - stimulation
INSIDE: Your Asthma Journey Step By Step
8229 Boone Blvd. Suite 260 Vienna, VA 22182 800.878.4403 www.aanma.org info@aanma.org Understanding Asthma: Building Blocks For Better Breathing Allergy & Asthma Today Special Edition is published by Allergy
Doncaster & Bassetlaw Medicines Formulary
Doncaster & Bassetlaw Medicines Formulary Section 3.2: Corticosteroids Beclometasone 50, 100 and 250micrograms/dose Clickhaler Clenil Modulite (Beclometasone CFC free) 50, 100, and 250micrograms/dose MDI
Evaluating Steroid Inhalers Used to Treat: Asthma and Chronic Lung Disease. Comparing Effectiveness, Safety, and Price
Evaluating Steroid Inhalers Used to Treat: Asthma and Chronic Lung Disease Comparing Effectiveness, Safety, and Price Our Recommendations Inhaled steroids are effective and safe medicines used to treat
Problems With Inhaler Use: A Call for Improved Clinician and Patient Education
Problems With Inhaler Use: A Call for Improved Clinician and Patient Education James B Fink MSc RRT FAARC and Bruce K Rubin MEngr MD MBA FAARC Introduction Economic Impact of Inhaler Misuse Problems With
Asthma Intervention. An Independent Licensee of the Blue Cross and Blue Shield Association.
Asthma Intervention 1. Primary disease education Member will have an increased understanding of asthma and the classification by severity, the risks and the complications. Define asthma Explain how lungs
A VNSNY SELF-CARE GUIDE
A VNSNY SELF-CARE GUIDE For the Management of: Chronic Obstructive Pulmonary Disease (COPD) Visiting Nurse Service of New York A PATIENT SELF-CARE GUIDE FOR THE MANAGEMENT OF: Chronic Obstructive Pulmonary
How to Manage Asthma in Children
Clinical Guideline for the Diagnosis, Evaluation and Management of Adults and Children with Asthma Color Key n Four Components of Asthma Care n Classifying Asthma Severity, Assessing Asthma Control and
MEDICATION GUIDE. SYMBICORT 80/4.5 (budesonide 80 mcg and formoterol fumarate dihydrate 4.5 mcg) Inhalation Aerosol
MEDICATION GUIDE SYMBICORT 80/4.5 (budesonide 80 mcg and formoterol fumarate dihydrate 4.5 mcg) Inhalation Aerosol SYMBICORT 160/4.5 (budesonide 160 mcg and formoterol fumarate dihydrate 4.5 mcg) Inhalation
TACVPR Newsletter. Winter 2014. A Message from Your President. Texas Association of Cardiovascular & Pulmonary Rehabilitation
TACVPR Newsletter Texas Association of Cardiovascular & Pulmonary Rehabilitation A Message from Your President Winter 2014 Happy New Year! I hope you enjoyed your holidays and had time to spend with family
Irish Association for Emergency Medicine (IAEM) submission to the National COPD Strategy
31 st Irish Association for Emergency Medicine (IAEM) submission to the National COPD Strategy 1 Introduction Chronic obstructive pulmonary disease (COPD) is an important disease for patients, the health
Objectives COPD. Chronic Obstructive Pulmonary Disease (COPD) 4/19/2011
Objectives Discuss assessment findings and treatment for: Chronic Obstructive Pulmonary Disease Bronchitis Emphysema Asthma Anaphylaxis Other respiratory issues Provide some definitions Chronic Obstructive
AETNA BETTER HEALTH Prior Authorization guidelines for Step Therapy
AETNA BETTER HEALTH Prior Authorization guidelines for Step Therapy Definition A form of automated Prior Authorization whereby one or more prerequisite medications, which may or may not be in the same
- Canine Chronic Bronchitis cannot be cured, but can be controlled
MD-096A-0211 1 2 - The symptoms of asthma can mimic other diseases such as heartworm, pneumonia and congestive heart failure (Padrid, Use of Inhaled Medications to Treat Respiratory Diseases in Dogs and
Exploratory data: COPD and blood eosinophils. David Price: 9.23-9.35am
Exploratory data: COPD and blood eosinophils David Price: 9.23-9.35am Blood Eosinophilia in COPD The reliability and utility of blood eosinophils as a marker of disease burden, healthcare resource utilisation
The. Treating patients with COPD with medications
Treating patients with COPD with medications Gilbert E. D Alonzo Jr, MS, DO, FACOI; Fredric Jaffe, DO, FCCP; Samuel L. Krachman, DO SHUTTERSTOCK.COM The management treatment of chronic obstructive pulmonary
STAYING ASTHMA FREE. All you need to know about preventers. www.spacetobreathe.co.nz
STAYING ASTHMA FREE All you need to know about preventers www.spacetobreathe.co.nz HELPING YOUR CHILD BREATHE MORE EASILY GETTING TO KNOW THE PREVENTER What is a preventer? When do you use it? How do they
Welcome COPD MANAGEMENT PROGRAM. Reproduced with permission of UofL Pulmonary s COPD Management Program
Welcome COPD MANAGEMENT PROGRAM Section 1: Section 2: Section 3: Section 4: Section 5: Section 6: Section 7: Section 8: Section 9: What is COPD? How the Lungs work. Managing your COPD. Exercise Breathing
Tests. Pulmonary Functions
Pulmonary Functions Tests Static lung functions volumes Dynamic lung functions volume and velocity Dynamic Tests Velocity dependent on Airway resistance Resistance of lung tissue to change in shape Dynamic
The Annual Direct Care of Asthma
The Annual Direct Care of Asthma The annual direct health care cost of asthma in the United States is approximately $11.5 billion; indirect costs (e.g. lost productivity) add another $4.6 billion for a
Objectives. Asthma Management
Objectives Asthma Management BREATHE Conference Allergy and Asthma Specialists PC Christine Malloy MD March 22, 2013 Review the role of inflammation in asthma Discuss the components of the EPR-3 management
MEDICATION INFORMATION: CONTROLLER MEDICATIONS
FRANK J. TWAROG, M.D., Ph.D. CURTIS T. MOODY, M.D. ADULT AND PEDIATRIC ASTHMA AND ALLERGIES Brookline Concord (617) 735-8750 (978) 369-3567 MEDICATION INFORMATION: CONTROLLER MEDICATIONS Asthma medications
CURRICULUM VITAE KIRK GEORGE VOELKER, M.D.
PERSONAL INFORMATION DATE OF BIRTH December 29, 1961 PLACE OF BIRTH OFFICE ADDRESS E-MAIL Buffalo, NY. 1537 State St. 34236 (941) 330-1696 Dr.Voelker@comcast.net ACADEMIC RECORD UNDERGRADUATE MEDICAL SCHOOL
PULMONARY ALLERGY DRUGS ADVISORY COMMITTEE MEETING
PULMONARY ALLERGY DRUGS ADVISORY COMMITTEE MEETING FDA Briefing Document March 7, 213 NDA 24-275: fluticasone furoate and vilanterol inhalation powder for the long-term, maintenance treatment of airflow
Attached is updated information for HEDIS 2015 specifications relating to Respiratory Conditions:
TO: Providers to FHCP Members FROM: FHCP Quality Management RE: Update on HEDIS Quality Measures for 2015 FHCP follows current clinical practice guidelines and we are monitored by HEDIS (Healthcare Effectiveness
United States. 2013 Land Line And Cell Phone Codebook Report. CHILD Asthma Call-Back Survey
ACBS_2013_CHILD_PUBLIC_LLCP United States 2013 Land Line And Cell Phone Codebook Report CHILD Asthma Call-Back Survey April 29, 2015 STATE FIPS CODE Column: 1-2 Description: STATE FIPS CODE. SAS Variable
understanding the professional guidelines
SEVERE ASTHMA understanding the professional guidelines This guide includes information on what the European Respiratory Society (ERS) and the American Thoracic Society (ATS) have said about severe asthma.
RESPIRATORY PHARMACOLOGY
by Kevin T. Martin BVE, RRT, RCP RC Educational Consulting Services, Inc. 16781 Van Buren Blvd, Suite B, Riverside, CA 92504-5798 (800) 441-LUNG / (877) 367-NURS www.rcecs.com BEHAVIORAL OBJECTIVES UPON
Insights for Improvement: Advancing COPD Care Through Quality Measurement. An NCQA Insights for Improvement Publication
2009 Insights for Improvement: Advancing COPD Care Through Quality Measurement An NCQA Insights for Improvement Publication Chronic obstructive pulmonary disease (COPD) includes chronic bronchitis, emphysema,
Breathing BETTER. A handbook for people with COPD and other chronic lung conditions. 2010-2015 Intermountain Healthcare.
Breathing BETTER A handbook for people with COPD and other chronic lung conditions 2010-2015 Intermountain Healthcare. This booklet can help you learn how to breathe better, do more, and live well with
Dear Provider: Sincerely,
Asthma Toolkit Dear Provider: L.A. Care is pleased to present this updated asthma toolkit. Our goal is to promote the highest level of asthma care, based on the 2007 National Asthma Education and Prevention
Asthma in Infancy, Childhood and Adolescence. Presented by Frederick Lloyd, MD Palo Alto Medical Foundation Palo Alto, California
Asthma in Infancy, Childhood and Adolescence Presented by Frederick Lloyd, MD Palo Alto Medical Foundation Palo Alto, California Major Health Problem in Childhood Afflicts 2.7 million children in the USA
Medication and Devices for Chronic Obstructive Pulmonary Disease (COPD)
Medication and Devices for Chronic Obstructive Pulmonary Disease (COPD) Patients with COPD take a wide variety of medicines to manage their symptoms these include: Inhaled Short Acting Bronchodilators
Pulmonary Diseases. Lung Disease: Pathophysiology, Medical and Exercise Programming. Overview of Pathophysiology
Lung Disease: Pathophysiology, Medical and Exercise Programming Overview of Pathophysiology Ventilatory Impairments Increased airway resistance Reduced compliance Increased work of breathing Ventilatory
Medication Guide DULERA [dew-lair-ah] 100 mcg/5 mcg DULERA 200 mcg/5 mcg
![Medication Guide DULERA [dew-lair-ah] 100 mcg/5 mcg DULERA 200 mcg/5 mcg](/thumbs/33/15949075.jpg "Medication Guide DULERA [dew-lair-ah] 100 mcg/5 mcg DULERA 200 mcg/5 mcg")
Medication Guide DULERA [dew-lair-ah] 100 mcg/5 mcg (mometasone furoate 100 mcg and formoterol fumarate dihydrate 5 mcg inhalation aerosol) DULERA 200 mcg/5 mcg (mometasone furoate 200 mcg and formoterol
An Overview of Asthma - Diagnosis and Treatment
An Overview of Asthma - Diagnosis and Treatment Asthma is a common chronic disorder of the airways that is complex and characterized by variable and recurring symptoms, airflow obstruction, bronchial hyperresponsiveness,
is working on is about nutrition, specifically as it pertains to Alpha- continued on page 2
Alpha-1 Canada Update May 2010 It has been very busy here over the last few months. Well it always seems to be busy, but lately exceptionally so. As this newsletter goes to press we are only days away
Management of Asthma
Federal Bureau of Prisons Clinical Practice Guidelines May 2013 Clinical guidelines are made available to the public for informational purposes only. The Federal Bureau of Prisons (BOP) does not warrant
James F. Kravec, M.D., F.A.C.P
James F. Kravec, M.D., F.A.C.P Chairman, Department of Internal Medicine, St. Elizabeth Health Center Chair, General Internal Medicine, Northeast Ohio Medical University Associate Medical Director, Hospice
The asthmatic patient and sedation
The asthmatic patient and sedation Introduction The sedation practitioner is often faced with difficult questions to answer before the administration of sedation. Our guidelines say clearly that we are
Department of Surgery
What is emphysema? 2004 Regents of the University of Michigan Emphysema is a chronic disease of the lungs characterized by thinning and overexpansion of the lung-like blisters (bullae) in the lung tissue.
Chronic Obstructive Pulmonary Disease (COPD) Admission Order Set
Patient Name: PHN: Page 1/1 Admit to Dr: Notified Consult: Dr: Family Dr: Precautions: Contact Droplet Enhanced Droplet Airborne - Reason: _ Code Status: Full Resuscitation or Consults: Reason: Dietician
Medicare C/D Medical Coverage Policy
Nebulizer Medications Origination: June 17, 2009 Review Date: October 21, 2015 Next Review: October, 2017 Medicare C/D Medical Coverage Policy DESCRIPTION Nebulizer medications are used to prevent and
NEWS NP S. Inside. Defining COPD. Is it COPD? National Prescribing Service Newsletter
NP S NEWS National Prescribing Service Newsletter 5 1999 ISSN 1441-7421 Aug 99 Inside Bronchodilators and corticosteroids: Their use in COPD Give it up the best advice for COPD patients: NRT can help This